Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
AG Plenus Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner in 1 distinct art unit, which points to a focused prosecution strategy. The company's current patent office activity is concentrated, requiring a precise response to the specific issues raised by the assigned examiner. This focus within the Biotechnology & Pharmaceuticals field suggests that the company is prioritizing a specific innovation or protecting a key piece of its intellectual property portfolio.
JOHNSON, DANIELLE D is the busiest examiner for this portfolio, with 1 pending office action under review. This single action accounts for the company's entire pending workload at this time. Because the portfolio involves only 1 distinct examiner and 1 distinct art unit, the practitioner can dedicate resources to the specific nuances of this case. Successfully resolving the 1 pending office action will require a deep understanding of the requirements of the assigned examiner and the technical standards of the 1 distinct art unit. The company's immediate future in the Biotechnology & Pharmaceuticals sector is closely tied to the resolution of this 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, DANIELLE D | 1 | 45.0% | +13.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025401 | HERBICIDAL COMPOUNDS AND METHODS OF USE THEREOF | JOHNSON, DANIELLE D | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18025401 | HERBICIDAL COMPOUNDS AND METHODS OF USE THEREOF | JOHNSON, DANIELLE D | 1617 | §103Other | Final Rejection | — | Pending | Mar 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAG Plenus Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Danielle D Johnson has the most, with 1 of AG Plenus Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.